LSP leads € 15M series A round of Cardiovascular start-up Cardior Pharmaceuticals



Munich, Germany — May 11, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Cardior Pharmaceuticals, a private German company developing novel therapies for cardiovascular disease. The round of €15m was led by LSP, alongside BioMedPartners (with its new BioMedInvest III Fund), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF).
 
The funding will support the development of two assets in Cardiovascular Disease. Myocardial infarction (MI) is the most important cause of heart failure, a life-threatening condition affecting a large number of hospitalized people in industrialized countries. Current treatment options for heart failure patients are symptomatic and fail to address the disease causing molecular pathways. In a significant number of patients myocardial infarction leads to progressive structural remodeling of the heart resulting in early heart failure. Cardior’s founder Prof Thomas Thum discovered distinctive non-coding RNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. The assets developed by Cardior represent first-in-class non-coding RNA therapeutics and diagnostics for patients with myocardial infarction and heart failure. The funding is further aimed at advancing several discovery programs that focus on undisclosed targets that play a role in maladaptive remodeling of the heart.
 
“We are very excited to be leading this financing” said Dr Joachim Rothe, Managing Partner at LSP and a director of Cardior, “there has been a painful lack of scientific and clinical progress in the cardiovascular field for the past 15 years, and Cardior is well positioned to change this”.
 
Dr Claudia Ulbrich, CEO of Cardior says “It is a rare opportunity to develop cutting-edge science in the area of cardiovascular diseases with high unmet medical need. I am delighted to join Cardior at this exciting development stage of the company and together with its motivated team, quickly put on the map a novel class of drugs and companion diagnostics with the potential to prevent and overcome heart failure”.
 
A link to the company's press release can be found at here
 
About Cardior Pharmaceuticals 
Cardior Pharmaceuticals is a privately held German biotech company pioneering the next generation of non-coding RNA based therapeutics in heart failure. Prof Thomas Thum and his team have built a worldwide renowned expertise in the non-coding RNA field. In their scientific work they showed that the targeting of certain specific non-coding RNAs reverses maladaptive cardiac remodeling and restores normal cardiac function. In 2016 Cardior was founded as a spin-off from Hannover Medical School’s, one of Europe's leading medical centers.
 
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders in the global life-science industry. With over EUR 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.
 
Contact: 
Dr. Joachim Rothe
Managing Partner LSP
+49 89 330 666 0
webgur@yfcip.pbz
 
Dr. Karin Kleinhans
Associate LSP
+49 89 330 666 0
xxyrvaunaf@yfcip.pbz
« back to overview

LSP leads € 15M series A round of Cardiovascular start-up Cardior Pharmaceuticals



Munich, Germany — May 11, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Cardior Pharmaceuticals, a private German company developing novel therapies for cardiovascular disease. The round of €15m was led by LSP, alongside BioMedPartners (with its new BioMedInvest III Fund), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF).
 
The funding will support the development of two assets in Cardiovascular Disease. Myocardial infarction (MI) is the most important cause of heart failure, a life-threatening condition affecting a large number of hospitalized people in industrialized countries. Current treatment options for heart failure patients are symptomatic and fail to address the disease causing molecular pathways. In a significant number of patients myocardial infarction leads to progressive structural remodeling of the heart resulting in early heart failure. Cardior’s founder Prof Thomas Thum discovered distinctive non-coding RNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. The assets developed by Cardior represent first-in-class non-coding RNA therapeutics and diagnostics for patients with myocardial infarction and heart failure. The funding is further aimed at advancing several discovery programs that focus on undisclosed targets that play a role in maladaptive remodeling of the heart.
 
“We are very excited to be leading this financing” said Dr Joachim Rothe, Managing Partner at LSP and a director of Cardior, “there has been a painful lack of scientific and clinical progress in the cardiovascular field for the past 15 years, and Cardior is well positioned to change this”.
 
Dr Claudia Ulbrich, CEO of Cardior says “It is a rare opportunity to develop cutting-edge science in the area of cardiovascular diseases with high unmet medical need. I am delighted to join Cardior at this exciting development stage of the company and together with its motivated team, quickly put on the map a novel class of drugs and companion diagnostics with the potential to prevent and overcome heart failure”.
 
A link to the company's press release can be found at here
 
About Cardior Pharmaceuticals 
Cardior Pharmaceuticals is a privately held German biotech company pioneering the next generation of non-coding RNA based therapeutics in heart failure. Prof Thomas Thum and his team have built a worldwide renowned expertise in the non-coding RNA field. In their scientific work they showed that the targeting of certain specific non-coding RNAs reverses maladaptive cardiac remodeling and restores normal cardiac function. In 2016 Cardior was founded as a spin-off from Hannover Medical School’s, one of Europe's leading medical centers.
 
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders in the global life-science industry. With over EUR 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.
 
Contact: 
Dr. Joachim Rothe
Managing Partner LSP
+49 89 330 666 0
webgur@yfcip.pbz
 
Dr. Karin Kleinhans
Associate LSP
+49 89 330 666 0
xxyrvaunaf@yfcip.pbz
« back to overview